News ImmunityBio rises as route opens to broader Anktiva label Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.
News Data builds behind Moderna's skin cancer vaccine Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.
News AstraZeneca pays $630m to get full control of AbelZeta CAR-T AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.
Digital The role of AI technologies in precision oncology By focusing on assistance to the front-line oncologist, AI can enable improved diagnosis, clinical trials, and timely, accurate decision making.
News EU starts review of first-line Enhertu for breast cancer EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.
News NICE relents, ending postcode access to prostate cancer drug Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.